Efficacy and safety of commercial CD19 CAR-T (inaticabtagene autoleucel) in relapsed/refractory extramedullary B-ALL: A large multicenter real-world study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Soochow University, First Affiliated Hospital of Soochow University, Shanghai Jiao Tong University, Ruijin Hospital, Wuhan Union Hospital, Huazhong University of Science and Technology, Shanghai First People's Hospital, Zhujiang Hospital, Southern Medical University, First Affiliated Hospital Zhejiang University, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical College Hospital, Jiangsu Province Hospital, Henan Cancer Hospital, First Affiliated Hospital of Jinan University, Chinese PLA General Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Second Military Medical University, Tongji University, Fujian Medical University
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162690904
Cites:
Cited by:
Related to: